We have changed our domainWe have changed servers and operate Career|edu under a different domain. Our services will remain unchanged and we will continue to post the best career openings for the academic world at our new domain.
Go back to the Job List
Targeting eEF1A2-governed Regulation of Ribosomal Biogenesis in CancerPosted by: National Institutes of Health (NIH)
Posted date: 2020-Jan-02
A post-doctoral position in cell biology and translational oncology is available in the laboratory of Dr. R. Rudloff, Rare Tumor Initiative (RTI), Pediatric Oncology Branch (POB), National Cancer Institute at the main campus in Bethesda, MD.
Our lab is focused on drug discovery and drug development for patients afflicted by solid organ cancers. Metarrestin, a first-in-class small molecule developed by our lab in collaboration with the National Center for Advancing Translational Sciences (NCATS) is entering phase I clinical testing in 2020. Metarrestin selectively targets the translation elongation factor eEF1A2 in cancer cells inhibiting nucleolar ribosomal pre-assembly, polymerase I transcription, and ribosomal biogenesis. In parallel to its clinical development at the Center of Cancer Research as well as pharmacokinetic and toxicokinetic studies in genome-edited mice, we seek to understand the molecular and cellular mechanism of action of the agent and its target. Using a multi-disciplinary approach which includes structural biologists, medicinal chemists, biochemists, ultrastructural pathologists, and cell and molecular biologists, specifically, we aim to understand the cellular functions, protein-protein interactions, translational, and transcriptional mechanism how eEF1A2 regulates the BoPeW (BOP1, PES1, WDR12) complex, polymerase I transcription, and ribosomal biogenesis. Findings are aimed to be translated into novel drug target(s) and future leads for combination partners.Relevant Publications:
Frankowski K et al. Science Transl Med 2018, 10: 441-455. PMID: 29769289
Vilimas T et al. Cancer Chemother Pharmacol 2018, 82: 1067-1080. PMID: 30306263Qualifications:
This position is particularly suited for applicants who have recently (within 2 years) completed their PhD, MD/PhD, or equivalent degree, and seek a career in translational sciences and drug development. There are multiple training opportunities available including training at our partners at NCATS (located in Rockville, MD; about 20 minutes from main campus). Previous experience in protein chemistry and biochemistry is advantageous, the candidate needs to possess good communication skills.To Apply:
Please send a cover letter describing current interests, previous research experience, and future goals and current CV including names and contact address of three references by February 15th 2020 to rudloffumail.nih.gov. For more information on our laboratory, please visit https://ccr.cancer.gov/Pediatric-Oncology-Branch/udo-rudloff
HHS and NIH are Equal Opportunity Employers. The NIH is dedicated to building a diverse community in its training and employment programs. Minorities and women are especially encouraged to apply.